Abstract 247P
Background
To determine the p53 gene suppressor and bcl-2 oncoprotein forecast role in non-epithelial ovarian tumor prognosis among child and adolescent patients.
Methods
Our search is based on immunohistochemical method results of 35 patients with non-epithelial ovarian tumors at I-IV stages, which were diagnosed and treated in oncogynecology and children oncology departments .
Results
The analysis of immunohistochemical method results shows 7(20%) patients among which had been marked high expression bcl-2 oncoprotein, 11(31,4%) moderate express, 16(45,7%) low express. Analysis of p53 gene suppressor results shows 9(25,7%) patients among which had been marked high expression, 11(31,4%) moderate express, 15(42,8%) low express. The high correlation between bcl-2 expression level increases and fast tumor growth, and therefore incurability of oncologic process among of patients had been revealed. Also the high probability of tumor recurrence was noticed. In the high-positive p53 gene suppressor rate group took place aggressive current of tumor process and these patients had early recurrence and metastases, which demanded recurrent aggressive chemotherapy
Conclusions
p53 gene suppressor and bcl-2 oncoprotein expression in non-epithelial ovarian tumors among the child and adolescent patients is characterized with high and low rates, which enables to use this rate determination for given pathology currency prognosis identification.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
183P - Textbook outcome as a measure of surgical quality assessment and prognosis in gastric neuroendocrine carcinoma: A large multicenter sample analysis
Presenter: You-Xin Gao
Session: e-Poster Display Session
184P - Development and external validation of a nomogram to predict recurrence-free survival after R0 resection for stage II/III gastric adenocarcinoma: An international multicenter study
Presenter: Bin-Bin Xu
Session: e-Poster Display Session
185P - Effect of sarcopenia on short- and long-term outcomes of patients with gastric neuroendocrine tumour after radical surgery: Results from a large, two-institutional series
Presenter: Ling-Qian Wang
Session: e-Poster Display Session
186P - Characterization of the gastroenteropancreatic neuroendocrine tumour patient journey
Presenter: George Fisher Jr
Session: e-Poster Display Session
187P - More is not always better: A multicenter study in lymphadenectomy during gastrectomy for gastric neuroendocrine carcinoma
Presenter: Qi-Yue Chen
Session: e-Poster Display Session
188P - The impact of sarcopenia on chemotherapy toxicity and survival rate among pancreatic cancer patients who underwent chemotherapy: A systematic review and meta-analysis
Presenter: Billy Susanto
Session: e-Poster Display Session
189P - Prognostic value of inflammation-based score for patients treated with FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (GnP)
Presenter: Takahiro Yamamura
Session: e-Poster Display Session
190P - Outcomes from the Asian region of the phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for patients (pts) with resected pancreatic cancer (PC)
Presenter: Joon Oh Park
Session: e-Poster Display Session
191P - First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Results from a phase I/II study
Presenter: Andrew Dean
Session: e-Poster Display Session
192P - A multicenter crossover analysis of first and second-line FOLFIRINOX or gemcitabine plus nab-paclitaxel administered to pancreatic cancer patients: Results from the NAPOLEON study
Presenter: Kenta Nio
Session: e-Poster Display Session